AYTU (Aytu BioPharma) Other Current Liabilities: $8.03 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AYTU Aytu BioPharma Inc AYTU
40 GF Score
Price $2.20
GF Value $0.85
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Aytu BioPharma Other Current Liabilities?

Aytu BioPharma AYTU +0.92% 40 Other Current Liabilities is $8.03 Mil as of Mar. 2026. GuruFocus rates AYTU with a GF Score™ of 40/100 and a GF Value™ of $0.85 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Aytu BioPharma's other current liabilities for the quarter that ended in Mar. 2026 was $8.03 Mil.

Aytu BioPharma's quarterly other current liabilities declined from Sep. 2025 ($9.71 Mil) to Dec. 2025 ($8.57 Mil) and declined from Dec. 2025 ($8.57 Mil) to Mar. 2026 ($8.03 Mil).

Aytu BioPharma's annual other current liabilities increased from Jun. 2023 ($18.54 Mil) to Jun. 2024 ($18.95 Mil) but then declined from Jun. 2024 ($18.95 Mil) to Jun. 2025 ($13.32 Mil).

Aytu BioPharma Other Current Liabilities Related Terms

Aytu BioPharma Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Aytu BioPharma's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aytu BioPharma Other Current Liabilities Chart

Aytu BioPharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.65 15.89 18.54 18.95 13.32

Aytu BioPharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.59 13.32 9.71 8.57 8.03
AYTU
40GF Score
Aytu BioPharma Inc AYTU
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aytu BioPharma Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $8.03 Mil mean?
Aytu BioPharma (AYTU) has a Other Current Liabilities of $8.03 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aytu BioPharma.
Is Aytu BioPharma's Other Current Liabilities too high?
Aytu BioPharma's current Other Current Liabilities is $8.03 Mil. Overall, Aytu BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's Other Current Liabilities compare to TXMD and CPHI?
Aytu BioPharma's Other Current Liabilities of $8.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Aytu BioPharma. Aytu BioPharma's current Other Current Liabilities is $8.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.85, compared to a current price of $2.20 — trading 158.8% above its estimated fair value. The current Other Current Liabilities is $8.03 Mil. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current Other Current Liabilities is $8.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aytu BioPharma (AYTU) Overvalued in 2026?

Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued. The current stock price of $2.20 is trading 158.8% above its estimated GF Value™ of $0.85. GuruFocus considers Aytu BioPharma to be Significantly Overvalued.

Key valuation signals for AYTU:

  • Other Current Liabilities: $8.03 Mil
  • GF Value™: $0.85 vs. price of $2.20 (158.8% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aytu BioPharma Business Description

Address 7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score

Get the complete analysis for AYTU

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.20
Price
$0.85
GF Value